24 March 2026 - Merck announced today that British Columbia, Non-Insured Health Benefits (NIHB), Nova Scotia, Quebec and Veterans Affairs Canada have added Winrevair (sotatercept) to their public drug formularies. 

As the first jurisdictions to implement public coverage following the completed pan-Canadian Pharmaceutical Alliance (pCPA) agreement, these listings mark an important step toward improving access for Canadians living with pulmonary arterial hypertension, a rare, progressive and life‑limiting disease.

Read Merck press release